Stage of Program: Clinical Stage Programs (2.0 and relevant 1.0 projects)
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer
AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1
A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas
Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers
Phase I Treatment of Urethral Strictures in Humans
When a scar, or stricture, forms along the urethra it impedes the flow of urine and causes other complications. James Yoo, M.D., Ph.D., and his team at Wake Forest University Health Sciences will use epithelial and smooth muscle cells, taken from the patient’s bladder, and layer them on to a synthetic tubular scaffold. The tube […]
Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy
A Double-Blind Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Progenitor Cells for the Treatment of Dysphagia
Patients with head and neck cancer often undergo surgery and/or radiation to remove the tumors. As a result, they may develop problems swallowing and this can lead to serious complications such as malnutrition, dehydration, social isolation, or a dependence on using a feeding tube. Patients may also inhale food or liquids into their lungs causing […]
PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS
BioEclipse combines two approaches – an immune cell called a cytokine-induced killer (CIK) cell and a virus engineered to kill cancer cells called an oncolytic virus (OV) – to create what they call “a multi-mechanistic, targeted treatment.” They will use the patient’s own immune cells and, in the lab, combine them with the OV. The […]